Age/sex | Primary Diagnosis | Medical History | History Family | Anti-PD1 Drug | Other chemo-toxins | Diabetes presentation | Random C-peptide and BG | Time After PD-1 | Ab titers before nivolumab* | Ab titers after nivolumab | HLA |
---|---|---|---|---|---|---|---|---|---|---|---|
34/F | NSCLC | None | No history of DM | Nivolumab | Carboplatin, pemetrexed | DKA, BG 739, HbA1C 7.1%, urine ketones >80 mg/dL | <0.1 ng/mL while BG 377 mg/dL | 2 wks | + GAD65 (> 250), + IA-2 (6.2), - IAA (< 0.4), + ZnT8 (64) | + GAD65 (> 30)a, + IA-2 (6.1), + IAA (0.4), - ZnT8 (13)b | A30:01,30:02 (A30) D09:CTZ,09:CTZ (DR9) |